Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Purple Biotech (PPBT) Other Operating Expenses (2017 - 2022)

Purple Biotech has reported Other Operating Expenses over the past 6 years, most recently at -$53000.0 for Q2 2022.

  • Quarterly Other Operating Expenses rose 13.11% to -$53000.0 in Q2 2022 from the year-ago period, while the trailing twelve-month figure was -$53000.0 through Dec 2022, down 101.71% year-over-year, with the annual reading at $20.3 million for FY2025, 126643.75% up from the prior year.
  • Other Operating Expenses was -$53000.0 for Q2 2022 at Purple Biotech, down from $3.0 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $3.0 million in Q4 2021 and troughed at -$775000.0 in Q4 2018.
  • The 5-year median for Other Operating Expenses is -$57000.0 (2021), against an average of $235000.0.
  • Year-over-year, Other Operating Expenses plummeted 120.02% in 2018 and then surged 2184.62% in 2021.
  • A 5-year view of Other Operating Expenses shows it stood at -$775000.0 in 2018, then surged by 67.74% to -$250000.0 in 2019, then skyrocketed by 42.8% to -$143000.0 in 2020, then surged by 2184.62% to $3.0 million in 2021, then crashed by 101.78% to -$53000.0 in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Other Operating Expenses are -$53000.0 (Q2 2022), $3.0 million (Q4 2021), and $91000.0 (Q3 2021).